Several biomarkers for immunotherapeutic efficacy of advanced NSCLC, such as tumor mutation burden (TMB), PD-L1, and tumor-infiltrating lymphocytes, have been revealed in previous publications (Kerr et al., 2015; Meng et al., 2015; High TMB Predicts Immunotherapy Benefit, 2018). Here, CD274 is linked to neoplasm.